Get the Stockscreener App
33.43
3.37%
-1.1746
Ultragenyx Pharmaceutical Inc stock is traded at $33.43, with a volume of 825.61K.
It is down -3.37% in the last 24 hours and up +7.13% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
See More
Previous Close:
$34.60
Open:
$34
24h Volume:
825.61K
Relative Volume:
0.54
Market Cap:
$3.22B
Revenue:
$610.16M
Net Income/Loss:
$-532.93M
P/E Ratio:
-6.0458
EPS:
-5.5287
Net Cash Flow:
$-442.30M
1W Performance:
-5.31%
1M Performance:
+7.13%
6M Performance:
-14.92%
1Y Performance:
-34.43%
1-Day Range:
$32.94
$34.96
1-Week Range:
$32.94
$35.95
52-Week Range:
$25.81
$53.47
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Compare RARE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
33.44 | 3.33B | 610.16M | -532.93M | -442.30M | -5.5287 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.69 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.80 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.61 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.11 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.82 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jul-28-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | William Blair | Outperform |
| Jun-06-24 | Upgrade | Goldman | Neutral → Buy |
| Apr-22-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
Is Ultragenyx Pharmaceutical Inc. stock attractive for long term wealth buildingOil Prices & Free Technical Pattern Based Buy Signals - newser.com
Why Ultragenyx Pharmaceutical Inc. stock appeals to dividend seekersJuly 2025 Price Swings & Weekly Breakout Stock Alerts - newser.com
Can Ultragenyx Pharmaceutical Inc. (UP0) stock surprise with quarterly results2025 Volume Leaders & Low Drawdown Momentum Trade Ideas - newser.com
Is this a good reentry point in Ultragenyx Pharmaceutical Inc.July 2025 Market Mood & Fast Exit and Entry Strategy Plans - newser.com
Is Ultragenyx Pharmaceutical Inc. stock a buy in volatile marketsAnalyst Downgrade & Community Verified Watchlist Alerts - newser.com
Pinnacle Associates Ltd. Sells 29,107 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Key metrics from Ultragenyx Pharmaceutical Inc.’s quarterly dataMarket Performance Summary & Proven Capital Preservation Tips - newser.com
Chart based analysis of Ultragenyx Pharmaceutical Inc. trendsEarnings Trend Report & Breakout Confirmation Alerts - newser.com
Is Ultragenyx Pharmaceutical Inc. still worth holding after the dipTrade Volume Summary & Verified Chart Pattern Trade Signals - newser.com
Is Ultragenyx Pharmaceutical Inc. stock a top momentum playTrade Entry Summary & High Yield Equity Trading Tips - newser.com
Can Ultragenyx Pharmaceutical Inc. stock sustain revenue growthJuly 2025 Short Interest & Low Risk High Reward Ideas - newser.com
How risky is Ultragenyx Pharmaceutical Inc. stock nowJuly 2025 Selloffs & Free Real-Time Volume Trigger Notifications - newser.com
Can Ultragenyx Pharmaceutical Inc. stock deliver sustainable ROEJuly 2025 Short Interest & Long-Term Growth Plans - newser.com
Is Ultragenyx Pharmaceutical Inc. stock attractive after correctionWatch List & Long Hold Capital Preservation Plans - newser.com
Y Intercept Hong Kong Ltd Grows Stake in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Is Ultragenyx Pharmaceutical Inc. stock dividend yield sustainablePortfolio Performance Report & Long-Term Investment Growth Plans - newser.com
Will Ultragenyx Pharmaceutical Inc. see short term momentum2025 Winners & Losers & Weekly Setup with High ROI Potential - newser.com
Will Ultragenyx Pharmaceutical Inc. stock benefit from upcoming earnings reports2025 Fundamental Recap & Risk Controlled Stock Alerts - newser.com
Earnings visualization tools for Ultragenyx Pharmaceutical Inc.Long Setup & Consistent Growth Stock Picks - newser.com
Ultragenyx Pharmaceutical Inc expected to post a loss of $1.23 a shareEarnings Preview - TradingView
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Exelixis (EXEL) - The Globe and Mail
Ultragenyx doses first subject in study of GTX-102 for angelman syndrome - Clinical Trials Arena
What hedge fund moves indicate for Ultragenyx Pharmaceutical Inc. (UP0) stockTreasury Yields & Daily Oversold Stock Bounce Ideas - newser.com
Emerald Mutual Fund Advisers Trust Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Can Ultragenyx Pharmaceutical Inc. stock weather global recessionJuly 2025 Market Mood & Verified Technical Trade Signals - newser.com
Can Ultragenyx Pharmaceutical Inc. (UP0) stock hold up in economic slowdownMarket Weekly Review & Safe Capital Growth Trade Ideas - newser.com
Will Ultragenyx Pharmaceutical Inc. stock remain a Wall Street favoriteMarket Performance Summary & Advanced Technical Analysis Signals - newser.com
Ultragenyx Pharmaceutical Inc. (RARE) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Ultragenyx Begins Dosing in Aurora Study for Angelman Syndrome - TipRanks
Ultragenyx (RARE) Begins Aurora Study for Angelman Syndrome Trea - GuruFocus
Ultragenyx Pharmaceutical Initiates Aurora Study for Angelman Syndrome - TradingView
Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups - The Manila Times
Ultragenyx (NASDAQ: RARE) doses 1st patient in GTX-102 study; ~60 across genotypes - Stock Titan
Emerald Advisers LLC Sells 54,826 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):